DPX-Survivac Treatment Continues to Show Promise in Women with Advanced Ovarian Cancer, Early Data Show

DPX-Survivac Treatment Continues to Show Promise in Women with Advanced Ovarian Cancer, Early Data Show
Treatment with DPX-Survivac plus intermittent low-dose cyclophosphamide continues to show promise in women with advanced recurrent ovarian cancer, the second part of a Phase 1/2 trial shows. Interim data from the first six patients revealed that five patients (83%) achieved stable disease, including two tumor regressions — although it was not enough to be called a partial response. Among these five patients, four (80%) had smaller tumors — five centimeters or less — at the study's start, confirming earlier Phase 1 findings that smaller tumors led to better responses to treatment. “We are encouraged by these early initial results and are committed to advancing this program quickly with the goal of providing an additional treatment option to patients with advanced ovarian cancer,” Frederic Ors, CEO of IMV, said in a press release. DPX-Survivac consists of small fractions of the survivin protein, which is broadly over-activated in most cancer types and promotes tumor growth, according to IMV. Survivin plays an essential role in supporting tumor blood vessel growth and promoting resistance to anti-cancer therapies. The therapy, administered as an injection under the skin, works by triggering a strong immune response against cancer cells producing the survivin protein, causing th
Subscribe or to access all post and page content.